A case of anti- *pityriasis versicolor* therapy that preserves healthy mycobiome

Mariusz Dyląg 1*, Ewa Leniak 2, Sebastian Gnat 3, Jacek C. Szepietowski 4 and Łukasz Kozubowski 5

**Abstract**

**Background:** The impact of *Malassezia* yeasts on skin mycobiome and health has received considerable attention recently. *Pityriasis versicolor* (PV), a common dermatosis caused by *Malassezia* genus worldwide, is a manifestation of dysbiosis. PV can be associated with hyper- and/or hypopigmented skin lesions. This disease entity is characterized by high percentage of relapses, which demands a proper antifungal therapy that is based on unambiguous species identification and drug susceptibility testing.

**Case presentation:** Comprehensive analysis of PV case in man presenting simultaneously hyper- and hypopigmented skin lesions was performed. Conventional and molecular diagnostic procedures revealed *Malassezia furfur* and *Malassezia sympodialis*, respectively as etiological agents of skin lesions observed. Susceptibility tests showed significantly lowered sensitivity of *M. furfur* cells to fluconazole. Based on susceptibility profiles local antifungal therapy with drugs characterized by entirely different mechanism of action was included.

**Conclusions:** Our study indicates that cases of PV represented by two types of skin lesions in one patient may be associated with distinct *Malassezia* species. Moreover, as observed in this case, each of the isolated etiological agents of PV may differ significantly in susceptibility to antifungals. This can significantly complicate the treatment of dermatosis, which by definition is associated with a significant percentage of relapses. In the presented case localized topical treatment was sufficient and successful while allowing maintaining the physiological mycobiome.

**Keywords:** *Malassezia*, Hyperpigmentation, Hypopigmentation, Dysbiosis, Treatment

---

**Background**

*Pityriasis versicolor* (PV) also known as *tinea versicolor* is caused by basidiomycetous yeasts of the genus *Malassezia*, characterized by lipid-dependent growth [1–3] and narrow specialization in the context of occupied ecological niches [2]. With respect to human skin, species of the genus *Malassezia* may have positive as well as negative health impact [4–6]. These lipophilic fungi are the most important components of human skin mycobiome [6–8]. It is widely accepted that the composition of the skin microbiome is critical for its health and condition [6, 7]. *Malassezia restricta, Malassezia globosa* and *Malassezia sympodialis* are the most often isolated species from the skin of healthy individuals [8–11]. Under certain conditions, however these *Malassezia* species, similar to other opportunistic pathogens, break out of the internal control of the host and overgrow leading to skin infections [5]. While on healthy skin *Malassezia* proliferates as budding yeast, during an outbreak state cells often develop into pseudohyphae leading to the development of typical symptoms associated with PV [5, 12]. Places on the human body particularly predisposed to the development of the above-mentioned disease include skin areas rich in sebum (source of triglycerides) produced by sebaceous glands [13]. Such pathomechanism of infection is most typical for *M. globosa* and *M. furfur*, but can also involve *M. restricta, Malassezia globosa* and *Malassezia sympodialis*.
sympodialis which are able to form pseudohyphae in human stratum corneum [14, 15] and are the most common etiological factors of PV worldwide [4, 16, 17]. PV is one of the most common superficial fungal infections, although does not pose a serious threat to the health or life of the patient [4, 12, 18]. PV is not accompanied by pain, and inflammation; itching, and exfoliation of the skin are rather mild [5, 18]. In most cases, PV poses a problem mainly of an aesthetic nature, due to the accompanying skin discoloration, taking the form of hyper- or hypopigmentation, the latter known as PV alba or PVa [19]. However, PV may be characterized by high percentage of relapses [19, 20], especially among residents of tropical regions [17, 20], or because of improper therapy [21]. PV also stands out from other fungal infections in the context of the spectrum of people predisposed to the development of this disease. Among the most important internal and external risk factors promoting development of PV are oily skin (rich in sebum), impaired hormonal balance, hyperhidrosis, administration of corticosteroids or broad-spectrum antibiotics, genetic predispositions, and high temperature and relative humidity that prevail in tropical and subtropical regions [5, 18, 22]. Unlike most of known fungal diseases, superficial infections caused by Malassezia yeasts most often affect adults in their prime of life, who are usually not inflicted by any serious underlying diseases [5, 23], what was also demonstrated in our previous study [24].

In this work, we describe PV case involving two various etiological factors of infection underlying two different clinical manifestations in one patient. In the case presented, M. furfur (strain Mf_MD2) and M. sympodialis (strain Msy_MD10) were isolated from hypopigmented and hyperpigmented skin lesions, respectively. The third strain, M. restricta (Mr_MD2) was isolated only from healthy skin around the neck and face of the patient, free of any visible skin lesions. Furthermore, in control examination of healthy skin of patient’s wife the same M. sympodialis as well M. restricta isolates, but not M. furfur was isolated. Based on clinical manifestations of the disease, examination in light of Wood lamp, and replicable results of conventional and molecular tests, we were able to deliver evidences on etiology of two clinical types of skin lesions. Importantly, this work demonstrates that use of topical antifungal drugs, applied only to affected skin, is sufficient to cure PV and simultaneously preserve skin mycobiome.

**Case presentation**

In October 2019, a 50-year-old fair complexion man, resident of Lower Silesia (Poland), construction manager by profession, after dermatological consultation was directed for a mycological examination to the local laboratory. The first skin changes patient observed on chest in May 2019 and then disease manifestations developed systematically. In an interview, the patient revealed that in August 2019, with no prior medical consultation, he administered an antifungal cream containing 0.5% fluconazole. According to the patient the treatment was irregular (i.e. two times per week for 2 weeks) and for this reason with no visible improvement. During the visit to the dermatologist, basic physical examinations and those using the Wood lamp and dermatoscope were carried out. On the day of consultation, extensive hyper- and hypopigmented macules on patient’s skin were diagnosed that were characterized by and with an uneven edges, moderate skin scaling and the accompanying mild itching, clearly visible when using a dermatoscope. Skin lesions covered the chest, shoulders, back, arms and forearms (Fig. 1a-c). Patches were not spilled, but took the form of numerous small beige discolorations, with the exception of forearms where patches were white and rather resembled vitiligo (Fig. 1d).
It should also be noted that forearms, due to sunlight exposure during many hours of construction work in the field, were clearly tanned, unlike other parts of the body where hyperpigmented macules were found. The patient was immunocompetent and in overall good health. Medical records and an interview indicated that neither the patient nor his family had any systemic, psychosomatic or chronic skin diseases. The patient had no prior history of immunosuppressive drugs treatments. Based on characteristic symptoms PV was diagnosed. The decision on the type of antifungal therapy was made based on the characteristic clinical symptoms of the disease, and the results of direct mycological examination, and susceptibility tests. Despite the fact that the skin lesions were quite widespread, oral treatment with systemic antifungal drugs was not included. This allowed to avoid interference with the composition of the gastrointestinal microbiome, and minimized disturbance of the mycobiome of healthy skin. After obtaining patient approval, at the beginning of November 2019, based on the results of the in vitro susceptibility tests, the therapy was set as follows: topical administration of ciclopirox 1% cream once daily (applied overnight), and terbinafine 1% emulsion gel applied once daily (in the morning) for 14 and 7 days, respectively. Direct microscopy examination of the skin scrapings, collected from hyper- and hypopigmented macules, performed 2 weeks after completed treatment, still revealed the presence of some fragments of pseudohyphae and single degenerated cells, while the results of cultures on modified Leeming-Notman agar (MLNA) were negative. In contrast to affected skin, pseudohyphae are typically absent in the material collected from healthy skin [5, 28], consistent with the case described here (Fig. 2b, e).

Discussion and conclusions
PV is most commonly manifested as hyperpigmented and/or hypopigmented skin lesions [5, 25–27]. A direct examination of skin scales from these lesions typically reveals abundant pseudohyphae and clusters of cells in a characteristic “spaghetti with meatballs” pattern [18], also observed in this study (Fig. 2a, c, d, f). In contrast to affected skin, pseudohyphae are typically absent in the material collected from healthy skin [5, 28], consistent with the case described here (Fig. 2b, e).

The coexistence of hypo- and hyperpigmented skin lesions has been described elsewhere [29–31]. However, in many of such cases there is no information if one or two etiological agent(s) caused these distinct lesions [30, 31]. Until the study reported by Gaitanis et al. [26], only one etiological factor of Malassezia genus has been perceived as associated with PV, regardless of the types of symptoms accompanying the disease. The study by Gaitanis et al. has provided an explanation for the dual nature of the etiology of hypo- and hyperpigmented skin lesions examined in six female patients [26]. However, the exact mechanisms leading to development of hyper- and hypopigmented lesions has not yet been fully elucidated, and several plausible explanations have been proposed [32–34]. The most probable seems the hypothesis pointing to dissimilarities in the ability to synthesize melanin by M. furfur and M. sympodialis, first time formulated by Gaitanis et al. [26] and later explained by Ianirii et al. based on molecular tools [35]. One of the causes of depigmenting effect, observed also in case of our patient on tanned skin of forearms and lower parts of arms (Fig. 1c), could be azelaic acid, which inhibits the melanogenesis process [32].

In the case study presented here, skin scrapings from two types of skin lesions in a single patient were collected separately and treated individually, as if the biological material originated from two separate disease entities. Such a diagnostic approach allowed
for isolating *M. sympodialis* and *M. furfur* as separate etiological factors of hyperpigmented and hypopigmented skin lesions, respectively. Interestingly, hypopigmented patches, localized on forearms and in the lower parts of arms (Fig. 1c), showed the yellow to yellow-orange fluorescence in the light of Wood's lamp. Positive results of examination under Wood's lamp are present only in about one third of the PV cases [4]. In documented cases of this type [4, 26], *M. furfur* was isolated from such lesions, suggesting this species contributes to the fluorescence detected under the Wood's lamp illumination. It is well established, based on experimental studies, that only *M. furfur* among all the species of the genus is able to synthesize specific indole compounds, including pityriarubins, malassezin and pityrialactones that, act as fluorochromes [4, 20, 33]. Unlike the macules on forearms and lower parts of the arms, hyperpigmented lesions showed lack of fluorescence under Wood's lamp and strikingly these regions contained only *M. sympodialis*, while *M. furfur* was not detected.

Although PV never leads to scars and most of currently known etiological factors of this disease are highly susceptible to commonly used antifungal drugs [21], occasionally it takes extended time to restore the skin’s original appearance [17, 36]. Regardless of what antifungal therapy has been applied to treat PV, it is often difficult to assess if the treatment has been effective. This is due to the fact that the dead fungal cells remain on the skin surface for several weeks after the therapy has been completed [18]. In the case study presented here, direct examination of the skin scrapings, which was performed 2 weeks after finished treatment, still revealed the presence of a small number of *Malassezia* cells. On the other hand, attempts to culture collected biological material have confirmed that both etiological factors of PV were killed although pigmentation changes were still present for several weeks, what was consistent with literature [17, 31]. However, these changes gradually subsided over the following weeks. Finally, direct microscopical examination performed 2 months after the therapy has been completed, revealed negative cultures on MLNA medium and confirmed a lack of structures typical for *Malassezia*. In contrast, control examination of unaffected skin around the neck and face performed after this time, still revealed the presence of *M. restricta* and *M. sympodialis* cells, what was confirmed by positive results of direct examination, as well as it was visible in the mixed culture of both isolates on the MLNA medium. Our case study showed

![Fig. 2 Histological patterns of fungal structures observed in skin scrapings. Skin scales taken from hypopigmented (a, d) and hyperpigmented (c, f) lesions, and for control from healthy skin around the neck and face of man (b, e). Microscopic preparations in DMSO with 10% KOH (a-c) or stained by PAS technique (d-f), magnification: a and c 1000x, d and f 400x, e 2000x, and b 3000x]
that whereas etiological factors of PV were effectively eradicated from the affected skin locations, in the areas of uninfected skin the normal lipid-dependent mycobiota was still present. Such an outcome was possible thanks to the global approach taking into account not only effective treatment of infection but also protection of microbiota present on healthy skin. With this in mind, the management of infection did not include systemic therapy, but utilized cream and gel, which were applied topically only to affected areas of the skin.

According to recent studies, the most abundant human skin inhabitants are M. globosa and M. restricta followed by M. sympodialis [1, 2, 9, 21]. In our case study, M. restricta and M. sympodialis were isolated from healthy skin of man and his wife as the most probable components of their normal skin mycobiota. Moreover, M. sympodialis, which was isolated as etiological factor of PV from hyperpigmented lesions, was isolated simultaneously from healthy skin around the face and neck of the patient and from the chest and neck of patient’s wife. Nucleotide sequences analysis for M. sympodialis isolates obtained both from man and his wife suggested the same strain, at least with respect to nucleotide sequences of the ITS region. During the control examination of women’s skin, M. furfur was never isolated. It cannot be excluded that one (or both) of identified etiological factors of PV in the man, typically as single blastoconidia, was (were) earlier normal component(s) of healthy skin mycobiome. Such a possibility is also very likely considering the fact that these species are described elsewhere as components of human skin mycobiome, although not as common as previously mentioned M. globosa and M. restricta [1, 2, 21].

Previously described cases suggest that some endogenous and/or exogenous factors may have occurred, leading to the dysbiosis [6] and development of typical disease symptoms [4, 22]. As it is described elsewhere [4, 5, 17], the disease symptoms usually appear when cell proliferation intensifies and mycelial growth is promoted within the tissue. Our results also point to a blurred borderline between physiological conditions and a pathological state where yeasts overgrow and cause the disease. All the presented herein facts allow to conclude that similar events led to the development of PV in the case studied here. Moreover, improper treatment with fluconazole executed by the patient, before visiting dermatologist, could have contributed to the acquired resistance of Malassezia to this drug.

Although, no reference method has been developed for Malassezia yeasts susceptibility testing, we decided to follow one of the newest and commonly cited protocols developed by Rojas et al. [37], which is closest to CLSI (Clinical & Laboratory Standards Institute) reference protocol [38]. Malassezia lipophilic fungi are generally seen as highly sensitive to commonly used topical and systemic drugs [21, 36]. For this reason, it is generally considered that patients afflicted by PV might be primarily treated with topical agents [19, 36]. However, special care and adequate monitoring should be ensured due to recurrence, which is frequently reported for PV and estimated to occur in ~60% and ~80% of patients in the first and the second year, respectively [19, 21]. On the other hand, an acquired resistance to fluconazole and otherazole drugs [39–41], commonly identified for Malassezia spp. in vitro, was an important reason to assess the susceptibility profiles of all three Malassezia strains. Results of susceptibility testing allowed the dermatologist to choose the best option for therapy. Considering this, the doctor included antifungal drugs representing two different classes i.e. allylamine (terbinafine) and hydroxypyridones (ciclopirox). These drugs are characterized by entirely different mechanism of action [42, 43]. Moreover, both these drugs have been used successfully against Malassezia species and were recommended [44]. While Malassezia yeasts are susceptible to azole-type, hydroxypyridone-type and allylamine-type drugs [21, 36, 45], the last mentioned are not effective given orally [46]. Taking this into consideration and based on the results of susceptibility tests (Table S1, additional file 1), local therapy including ciclopirox and terbinafine was selected. This approach was further justified given our results indicating low susceptibility of M. furfur (Mf_MD2 strain to fluconazole (Table S1, additional file 1). To elucidate the most probable mechanism of resistance to fluconazole, additional susceptibility tests were performed (Fig. S1, additional file 1) with rhodamine 6G and daunorubicin (described and discussed in details in, Additional file 1). While in the case presented here topical treatment was effective and no relapses were observed, cases of severe or recalcitrant PV may still require oral administration of itraconazole or fluconazole (excluding strains resistant to azoles). Problems related to therapy of PV, especially PVa are described elsewhere in more details including various treatment regimens [19].

Successful therapy in the case presented here was possible thanks to the unambiguous species identification (Table 1, Fig. 3). Herein should be also mentioned that non-culture-based molecular methods, described elsewhere [47, 48] are currently considered the best way to detect and identify Malassezia species from the clinical specimens. However, non-culture-based molecular methods although very effective do not make it possible
to state whether fungal specific structures are still viable or already killed by antifungal drug. To overcome this limitation, we decided to perform molecular identification based on pure cultures, which allowed monitoring the progress of antifungal therapy with respect to pathogen viability. For instance, examination performed after the first 2 weeks of therapy revealed that cultures on MLNA medium were negative while Malassezia specific structures were still visible during microscopic direct examination. Furthermore, the unambiguous species identification (Table 1, Fig. 3) allowed us to link the occurrence of hypo- and hyperpigmented skin lesions with separate etiological agents, *M. furfur* and *M. sympodialis*, respectively.

Both species can be a part of healthy skin mycobiome and under specific conditions can simultaneously cause PV [4, 8, 11, 17]. In the context of the infection and its management, *M. furfur* appears to be more problematic than *M. sympodialis*. This is evidenced by serious bloodstream infections so far only described for *M. furfur* [21]. In the context of superficial infections, this predominance may result from better predisposition of *M. furfur* to develop invasive mycelial form, which can penetrate human stratum corneum [5, 12, 15]. Also, unlike *M. sympodialis*, *M. furfur* is naturally able to synthesize specific fluorochromes, including indole derivatives [19, 20] and azelaic acid [32]. Both mentioned compounds have impact on the presentation of PV due to their negative effects on melanocytes and inhibition of the melanogenesis [19, 32–34] that can lead to white discoloration of skin resembling vitiligo [19]. Such effects may be the cause of skin discoloration, observed in our patient (Fig. 1c).

The species specific predisposition to synthesize of fluorochromes, that have the ability to absorb light of a certain wavelength and re-emit light at a longer wavelength, is an important element of the differential diagnosis based on the use of Wood's lamp [4, 20, 26]. Previous studies have indicated that hypopigmented lesions characterized by greenish-yellowish fluorescence in Wood's lamp were colonized by *M. furfur*, while hyperpigmented non-fluorescent areas of skin contained other species of the Malassezia genus including *M. sympodialis* [34]. Our study confirmed this relationship with both types of skin areas detected simultaneously in the same patient. *M. sympodialis*, in contrast to *M. furfur*, is characterized by the ability to synthesize melanin [26, 35], which may explain the characteristic appearance of hyperpigmented lesions [26]. In Malassezia diagnostics, the results of conventional tests based on pure cultures are often insufficient for unambiguous species identification. However, tests based on pure cultures presented here (Fig. 4 and, Additional file 1) provided additional support for molecular techniques and allowed for better

---

**Table 1** BLAST analysis of nucleotide sequences of the PCR-products obtained in amplification with ITS1 and ITS4 primers. All E-values were 0.0

| Identified species | GenBank Accession No. | Sequence length [bp] | Identity with sequence from GenBank |
|-------------------|-----------------------|----------------------|------------------------------------|
| *Malassezia furfur* | MN888953.1            | 789                  | 100 99.11 KY104128.1                |
| *Malassezia restricta* | MN888954.1             | 711                  | 82 96.93 AY387143.1                |
| *Malassezia sympodialis* | MN888952.1             | 621                  | 95 98.82 KY104182.1 and KY104176.1 |

*a*PCR Polymerase chain reaction; **ITS** Internal transcribed spacer; **E** value - BLAST E-value, number of expected hits of similar score that are available just by chance;  **bp** Base pairs
understanding of the biology and predisposition for pathogenicity of Malassezia species isolated in this work. We would like to point out that testing utilization of glycine is yet another useful diagnostic method, which while not performed in our studies, may be helpful in future investigations [49].

Our case study has demonstrated that the used topical antifungal drugs, characterized by different mechanisms of action was sufficient to cure PV without any relapses. However, further investigations including large study groups would be desirable. Such additional studies are necessary to shed more light on causative agents of...
hyperpigmented and hypopigmented cases of PV, especially when the two skin regions are found in the same patient. Moreover, future investigations should further evaluate the proceedings similar to those described here that allowed eradication of the infection while preserving the composition of the microbiome.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12895-020-00106-x.

Abbreviations
CLSI: Clinical & laboratory standards institute; MLNA: Modified Leeming-Notman agar; PCR: Polymerase chain reaction; PV: Pityriasis versicolor

Acknowledgements
The authors thank Prof. Eugeniusz Baran, M.D., Ph.D. for the clinical consultation, recommendations for antifungal therapy and all comments on the final version of the manuscript. The authors also thank Dr. Małgorzata Bień (University of Wrocław) for her help with fungal nomenclature, PAS staining technique and critical review with helpful comments on the manuscript.

Authors’ contributions
MD was responsible for the integrity of the manuscript as a whole, conception and design, conducting most of the experiments, analysis and interpretation of the data and preparing an initial draft of the article; EL was responsible for statistical analysis, validation and visualization of the results; ICS was responsible for supervision of all the experiments, manuscript editing and supervision of some molecular biology experiments; JCS was responsible for analysis of the results of the molecular identification and supervision of some molecular biology experiments; JCSS was responsible for molecular identification, Susceptibility tests and their interpretation, Table S1, Fig. S1; Supplementary references).

Availability of data and materials
All the datasets supporting the conclusions of this article are available and included within the main text of this work and its Additional file 1. Relevant nucleotide sequences and isolated strains are deposited in GenBank under accession numbers: MN888953.1; MN888954.1; MN888952.1 and in the Institute of Genetics and Microbiology, University of Wrocław, respectively.

Ethics approval and consent to participate
Ethics approval not applicable to this case report. Written informed consents for publication of clinical details and clinical images were obtained from the patient and his wife (non-patient).

Consent for publication
Written informed consent was obtained from the patient and his wife for publication of this case report and any accompanying images.

Competing interests
Authors have no competing interests to declare.

Author details
1 Department of Mycology and Genetics, Institute of Genetics and Microbiology, University of Wrocław, Wrocław, Poland. 2 Max Planck Institute of Molecular Plant Physiology, 14476 Potsdam, Germany. 3 Department of Veterinary Microbiology, Institute of Biological Bases of Animal Diseases, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Lublin, Poland. 4 Department of Dermatology, Venereology and Allergology Wrocław Medical University, Wrocław, Poland. 5 Department of Genetics and Biochemistry, Clemson University, Clemson, SC, USA.

References
1. Gaitanis G, Magiatis P, Hantschke M, Bassukas ID, Velegraki A. The Malassezia genus in skin and systemic diseases. Clin Microbiol Rev. 2012;25:106–41.
2. Wu G, Zhao H, Li C, et al. Genus-wide comparative genomics of Malassezia delineates its phylogeny, physiology, and niche adaptation on human skin. PLoS Genet. 2015;11:e1005614.
3. Tenagyi TR, Chen X, Iwatsui S, Kajiwara S. Long-chain acyl-CoA synthetase is associated with the growth of Malassezia spp. J Fungi (Basel). 2019;5:88.
4. Schwartz RA. Superficial fungal infections. Lancet. 2004;364:1173–82.
5. Plohic A, Jovovic Sadikovic T, Krupalija-Fazlic M, Kuskunovic-Vlahovlak S. Malassezia species in healthy skin and in dermatological conditions. Int J Dermatol. 2016;55:494–504.
6. Byrd A, Belkaid Y, Segre J. The human skin microbiome. Nat Rev Microbiol. 2018;16:143–55.
7. Findley K, Oh J, Yang J, et al. Topographic diversity of fungal and bacterial communities in human skin. Nature. 2013;498:667–70.
8. Sugita T, Zhang E, Tanaka T, et al. Recent advances in research on Malassezia microbiota in humans. Med Mycol J. 2013;5:439–44.
9. Sugita T, Suto H, Unno T, et al. Molecular analysis of Malassezia microflora on the skin of atopic dermatitis patients and healthy subjects. J Clin Microbiol. 2001;39:3486–90.
10. Kamamoto CSl, Nishikaku AS, Gompertz OF, Melo AS, Hassun KM, Bagatin E. Cutaneous fungal microbiome: Malassezia yeasts in seborrhoeic dermatitis scalp in a randomized, comparative and therapeutic trial. Dermatologendocrinol. 2017;9:e1361573.
11. Saxena R, Mittal P, Clavaud C, et al. Comparison of healthy and dandruff scalp microbiome reveals the role of commensals in scalp health. Front Cell Infect Mi. 2018;8:346.
12. Crespo-Erchiga V, Delgado-Florenflo V. Malassezia species in skin diseases. Curr Opin Infect Dis. 2002;15:133–42.
13. Harada K, Saito M, Sugita T, Tsuboi R. Malassezia species and their associated skin diseases. J Dermatol. 2015;42:250–7.
14. Faergemann J, Ausma J, Borgers M. In vitro activity of R126638 and ketoconazole against Malassezia species. Acta Derm-Venerolog. 2006;86:1–4.
15. Guo H, Boekhout T, Begerov H. Dendrology, phylogeny and ultrastructure. In: Boekhout T, Guo H, editors. Malassezia yeasts in skin and systemic diseases. Clin Microbiol Rev. 2012;25:106–41.
16. Aspiric C, Ara M, Varea M, Rezusta A, Rubio C. Isolation of Malassezia globosa and M. sympodialis from patients with pityriasis versicolor in Spain. Mycopathologia. 2002;154:111–7.
17. Crespo-Erchiga V, Delgado-Florenflo V. Malassezia yeasts and pityriasis versicolor. Curr Opin Infect Dis. 2006;19:133–47.
18. Crespo-Erchiga V, Hay RJ. Pityriasis Versicolor and other Malassezia skin diseases. In: Boekhout T, Guo H, editors. Malassezia yeasts in skin and systemic diseases. Berlin Heidelberg: Springer-Verlag; 2010. p. 17–63.
19. Thoma W, Krämer H-J, Mayser P. Pityriasis versicolor alba. JEDAV. 2005;19:147–52.
20. Mayser P, Willig G, Imkampe A, Thoma W, Arnold N, Monees T. Synthesis of fluorochromes and pigments in Malassezia furfur by use of tryptophan as the single nitrogen source. Mycoses. 1998;41:265–71.
21. Theelen B, Cafarchia C, Gaitanis G, Bassukas ID, Boekhout T, Dawson TL. Malassezia ecology, pathophysiology, and treatment. Med Mycol. 2018;56(Suppl 1):10–25.
22. Mendez-Tovar LJ. Pathogenesis of dermatophytosis and tinea versicolor. Clin Dermatol. 2010;28:185–9.
23. Hudson A, Sturgeon A, Peiris A. Tinea versicolor. JAMA. 2018;320:1396.
24. Szepietowski JC, Baran E, Wild E. Tinea versicolor: a prospective study. Korean J Med Mycol. 2000;5:108–12.
25. Park HJ, Lee YW, Choe YB, Ahn KJ. Skin characteristics in patients with Pityriasis versicolor using non-invasive method, MPAS. Ann Dermatol. 2012;24:444–52.
26. Gaitanis G, Chasapi V, Velegraki A. Novel application of the masson-Fontana stain for demonstrating Malassezia species melanin-like pigment production in vitro and in clinical specimens. J Clin Microbiol. 2005;43:4147–51.
27. Gupta D, Thappa DM. The enigma of color in tinea versicolor. Pigment Int. 2014;1:32–5.
28. Crespo Erchiga V, Ojeda Martos AA, Vera Casano A, Crespo Erchiga A, Sánchez FF. Isolation and identification of Malassezia spp. in pityriasis versicolor, seborrheic dermatitis and healthy skin. Rev Iberoam Micol. 1999;16(Suppl 1):16–21.
29. Kallini JR, Riaz F, Khachemoune A. Tinea versicolor in dark-skinned individuals. Int J Dermatol. 2014;53:137–41.
30. Acharya R, Gyawalee M. Uncommon presentation of Pityriasis versicolor; hyper and hypopigmentation in a same patient with variable treatment response. Our Dermatol Online. 2017;8:43–5.
31. Mathur M, Acharya P, Karki A, Kc N, Shah J. Dermoscopy pattern of pityriasis versicolor. Clin Cosmet Investig Dermat. 2019;12:303–9.
32. Schallreuter KU, Wood JW. A possible mechanism of action for azelaic acid in the human epidermis. Arch Dermatol Res. 1990;282:168–71.
33. Krämer H-J, Podobinska M, Bartsch A, et al. Malassezin, a novel agonist of the aryl hydrocarbon receptor from the yeast Malassezia furfur, induces apoptosis in primary human melanocytes. ChemBioChem. 2005;6:860–5.
34. Mayser P, Gaitanis G. Physiology and biochemistry. In: Boekhout T, Guého E, Mayser P, Velegraki A, editors. Malassezia and the skin: science and clinical practice. Berlin Heidelberg: Springer-Verlag; 2010. p. 121–37.
35. Ianiri G, Averette AF, Kingsbury JM, Heitman J, Idnurm A. Gene function analysis in the ubiquitous human commensal and pathogen Malassezia genus. mBio. 2016;7:e01853–16.
36. Gupta AK, Foley KA. Antifungal treatment for pityriasis versicolor. J Fungi (Basel). 2015;1:13–29.
37. Rojas FD, Sosa Mde L, Fernández MS, Cattana ME, Córdoba SB, Giustano GE. Antifungal susceptibility of Malassezia furfur, Malassezia sympodialis, and Malassezia globoza to azole drugs and amphotericin B evaluated using a broth microdilution method. Med Mycol. 2014;52:641–6.
38. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard. In: CLSI document M27-A3. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
39. Jesus FPK, Lautert C, Zanette RA, et al. In vitro susceptibility of fluconazole-susceptible and -resistant isolates of Malassezia pachydermatis against azoles. Vet Microbiol. 2011;152:161–4.
40. Iatta R, Figueredo LA, Montagna MT, Ottranto D, Cafarchia C. In vitro antifungal susceptibility of Malassezia furfur from bloodstream infections. J Med Microbiol. 2014;63:167–73.
41. Iatta R, Puntilli MR, Illuminati D, Ottranto D, Cafarchia C. The role of drug efflux pumps in Malassezia pachydermatis and Malassezia furfur defence against azoles. Mycoses. 2017;60:178–82.
42. IIahi A, Hadrich I, Neji S, Trabelsi H, Makni F, Ayadi A. Real-time PCR identification of six Malassezia species. Curr Microbiol. 2017;64:671–7.
43. Murai T, Nakamura Y, Kan R, Watanabe S, Hasegawa A. Differentiation of Malassezia furfur and Malassezia sympodialis by glycine utilization. Mycoses. 2002;45:180–3.